NASDAQ:BNTC Benitec Biopharma (BNTC) Stock Price, News & Analysis $13.24 +0.21 (+1.61%) Closing price 04:00 PM EasternExtended Trading$13.64 +0.40 (+3.06%) As of 05:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Benitec Biopharma Stock (NASDAQ:BNTC) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Benitec Biopharma alerts:Sign Up Key Stats Today's Range$12.82▼$13.2550-Day Range$10.93▼$14.9752-Week Range$8.06▼$17.15Volume45,169 shsAverage Volume42,102 shsMarket Capitalization$347.55 millionP/E RatioN/ADividend YieldN/APrice Target$26.00Consensus RatingBuy Company Overview Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California. Read More Benitec Biopharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks30th Percentile Overall ScoreBNTC MarketRank™: Benitec Biopharma scored higher than 30% of companies evaluated by MarketBeat, and ranked 805th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingBenitec Biopharma has received a consensus rating of Buy. The company's average rating score is 3.13, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageBenitec Biopharma has only been the subject of 1 research reports in the past 90 days.Read more about Benitec Biopharma's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Benitec Biopharma are expected to decrease in the coming year, from ($1.48) to ($2.31) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Benitec Biopharma is -8.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Benitec Biopharma is -8.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBenitec Biopharma has a P/B Ratio of 2.83. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Benitec Biopharma's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.52% of the float of Benitec Biopharma has been sold short.Short Interest Ratio / Days to CoverBenitec Biopharma has a short interest ratio ("days to cover") of 12.8, which indicates bearish sentiment.Change versus previous monthShort interest in Benitec Biopharma has recently decreased by 0.69%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBenitec Biopharma does not currently pay a dividend.Dividend GrowthBenitec Biopharma does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted5.52% of the float of Benitec Biopharma has been sold short.Short Interest Ratio / Days to CoverBenitec Biopharma has a short interest ratio ("days to cover") of 12.8, which indicates bearish sentiment.Change versus previous monthShort interest in Benitec Biopharma has recently decreased by 0.69%, indicating that investor sentiment is improving. News and Social Media2.4 / 5News Sentiment1.28 News SentimentBenitec Biopharma has a news sentiment score of 1.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.03 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Benitec Biopharma this week, compared to 2 articles on an average week. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Benitec Biopharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.30% of the stock of Benitec Biopharma is held by insiders.Percentage Held by Institutions52.19% of the stock of Benitec Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Benitec Biopharma's insider trading history. Receive BNTC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Benitec Biopharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BNTC Stock News HeadlinesWe're Interested To See How Benitec Biopharma (NASDAQ:BNTC) Uses Its Cash Hoard To GrowAugust 17, 2025 | finance.yahoo.comBenitec Biopharma Inc.: Benitec Biopharma Provides Operational UpdatesJuly 10, 2025 | finanznachrichten.deAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Trump’s Great Gain” has officially begun. Altucher believes select cryptos could turn $900 into $108,000 over the next 12 months — and he’s laying out the full gameplan in a new presentation.August 29 at 2:00 AM | Paradigm Press (Ad)Benitec Biopharma Ltd ADR News (BNTC) - Investing.comJuly 2, 2025 | investing.comBenitec Biopharma: An Under-The-Radar And Undervalued Gene Therapy DeveloperApril 15, 2025 | seekingalpha.comBenitec Biopharma price target raised to $20 from $18 at Citizens JMPApril 11, 2025 | markets.businessinsider.comBenitec Biopharma participates in a conference call with Cantor FitzgeraldApril 8, 2025 | markets.businessinsider.comInsiders Are Loving These 5 Tech and Biotech StocksApril 2, 2025 | 247wallst.comSee More Headlines BNTC Stock Analysis - Frequently Asked Questions How have BNTC shares performed this year? Benitec Biopharma's stock was trading at $12.63 on January 1st, 2025. Since then, BNTC shares have increased by 4.8% and is now trading at $13.24. How were Benitec Biopharma's earnings last quarter? Benitec Biopharma Limited (NASDAQ:BNTC) released its quarterly earnings results on Wednesday, May, 14th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.36) by $0.12. When did Benitec Biopharma's stock split? Benitec Biopharma's stock reverse split on the morning of Wednesday, July 26th 2023.The 1-17 reverse split was announced on Wednesday, July 26th 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, July 26th 2023. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split. When did Benitec Biopharma IPO? Benitec Biopharma (BNTC) raised $0 in an IPO on Thursday, August 6th 2015. The company issued 0 shares at $0.00 per share. BMO Capital Markets and Maxim Group LLC served as the underwriters for the IPO and Roth Capital Partners was co-manager. Who are Benitec Biopharma's major shareholders? Top institutional investors of Benitec Biopharma include Franklin Resources Inc. (10.29%), Geode Capital Management LLC (1.58%), Ameriprise Financial Inc. (0.42%) and Simplify Asset Management Inc. (0.26%). View institutional ownership trends. How do I buy shares of Benitec Biopharma? Shares of BNTC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Benitec Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Benitec Biopharma investors own include Amarin (AMRN), Pfizer (PFE), ADMA Biologics (ADMA), AVEO Pharmaceuticals (AVEO), BioLineRx (BLRX), Exelixis (EXEL) and Sorrento Therapeutics (SRNE). Company Calendar Last Earnings5/14/2025Today8/29/2025Next Earnings (Estimated)9/25/2025Fiscal Year End6/30/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BNTC CIK1808898 Webwww.benitec.com Phone510-780-0819Fax61 (0)3 9966-9923Employees20Year Founded2001Price Target and Rating Average Price Target for Benitec Biopharma$26.00 High Price Target$35.00 Low Price Target$17.00 Potential Upside/Downside+96.4%Consensus RatingBuy Rating Score (0-4)3.13 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($1.51) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$21.75 million Net MarginsN/A Pretax MarginN/A Return on Equity-38.26% Return on Assets-35.71% Debt Debt-to-Equity Ratio0.01 Current Ratio14.80 Quick Ratio14.80 Sales & Book Value Annual Sales$80 thousand Price / Sales4,344.38 Cash FlowN/A Price / Cash FlowN/A Book Value$4.68 per share Price / Book2.83Miscellaneous Outstanding Shares26,250,000Free Float25,909,000Market Cap$347.55 million OptionableNo Data Beta0.40 Social Links The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:BNTC) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Benitec Biopharma Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Benitec Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.